Dermatology Research and Practice最新文献

{"title":"Double Challenges for Scalp Health: A Review of the Pathogenesis and Treatment Strategies of Coexistence of Seborrheic Dermatitis and Androgenetic Alopecia.","authors":"Mengyan Zhu, Lifang Hu","doi":"10.1155/drp/8851971","DOIUrl":"https://doi.org/10.1155/drp/8851971","url":null,"abstract":"<p><p>Androgenetic alopecia (AGA) and seborrheic dermatitis (SD) are two common scalp disorders that frequently impair the quality of life and may coexist in a subset of patients across all genders. SD presents in 40%-50% of all patients diagnosed with AGA. Although these conditions are traditionally discussed separately, increasing evidence suggests that they may share overlapping pathogenic factors, including androgen-driven sebum hypersecretion, imbalance of the scalp microecology, barrier dysfunction, and inflammatory signaling. We propose an integrated framework for understanding SD-AGA coexistence, emphasizing the interplay among endocrine influences, sebum alterations, microbial imbalance, and inflammatory activation. Therefore, the management of patients with coexisting AGA and SD should move beyond single-target approaches and emphasize the restoration of scalp homeostasis, control of inflammatory cascades, and integration of antiandrogen therapy through comprehensive, individualized treatment strategies. This review may offer a new perspective for the combined management of these dual scalp disorders.</p>","PeriodicalId":11338,"journal":{"name":"Dermatology Research and Practice","volume":"2026 ","pages":"8851971"},"PeriodicalIF":2.0,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13650735/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149165154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing Mitochondrial Function, Oxidative Stress and Vitamin D Status in Dark-Skinned Patients With Keloid Disease.","authors":"Grant Hattingh, Janette Bester, Jaco Kotze, Alisa Phulukdaree, Evangeline Nortje","doi":"10.1155/drp/7086830","DOIUrl":"https://doi.org/10.1155/drp/7086830","url":null,"abstract":"<p><strong>Background: </strong>Keloid disease, marked by excessive fibrous tissue growth, is prevalent in dark-skinned individuals. Mitochondrial integrity is essential for wound healing through cytoskeletal remodelling. Altered mitochondrial morphology and reactive oxygen species (ROS) signalling may underlie keloid pathology, which may be worsened by vitamin D insufficiency.</p><p><strong>Aim: </strong>To investigate vitamin D status, mitochondrial function and oxidative stress in keloid disease.</p><p><strong>Methods: </strong>Keloid tissue and whole blood were collected from 44 dark-skinned patients (18-65 years). Plasma vitamin D levels were quantified by routine analysis. Plasma malondialdehyde (MDA), a lipid peroxidation marker, was measured using the thiobarbituric acid reactive substance assay. Mitochondrial DNA (mtDNA) integrity was assessed by quantitative PCR in keloid tissue, and mitochondrial morphology was examined with transmission electron microscopy (TEM).</p><p><strong>Results: </strong>Among the 44 patients, 30 had normal vitamin D levels, 13 had low levels and 1 was deficient. Oxidative stress marker, MDA and mtDNA integrity were similar across vitamin D groups. No association was observed between vitamin D and plasma MDA levels. An inverse relationship emerged between mtDNA integrity and plasma MDA (<i>r</i> = -0.5225, CI -0.751--0.0182, <i>p</i> = 0.0036), while vitamin D positively correlated with mtDNA integrity (<i>r</i> = 0.402, CI 0.052-0.665, <i>p</i> = 0.0224). TEM revealed subtle mitochondrial alterations in patients with low vitamin D, including reduced size, and double-membrane outlines were visible in several micrographs, whereas others showed less pronounced boundary contrast.</p><p><strong>Conclusion: </strong>Vitamin D insufficiency was uncommon in this cohort. While oxidative stress marker, MDA and mtDNA integrity did not differ by vitamin D status, structural mitochondrial changes were observed in dark-skinned keloid patients with low vitamin D.</p>","PeriodicalId":11338,"journal":{"name":"Dermatology Research and Practice","volume":"2026 ","pages":"7086830"},"PeriodicalIF":2.0,"publicationDate":"2026-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13635681/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149105251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Amharic Version of the Children's Dermatology Life Quality Index (CDLQI): Cross-Cultural Adaptation and Psychometric Evaluation.","authors":"Debisa Eshatu Wendimu, Abebaw Yeshambel Alemu, Derese Bekele Daba, Saba Maria Lambert, Tedros Nigusse, Sagni Chali Jira, Yematawork Kebede Aragaw, Feleke Tilahun Zewdu, Wosen Ketema Bedaso, Fikregabrail Aberra Kassa, Demekech Damte, Teklu Cherkose, Amel Beshir Mohammed, Fewzia Shikur Mohammed, Shimelis Nigussie Doni, Michael Marks, Endalamaw Gadisa, Stephen L Walker, Yohannes Hailemichael","doi":"10.1155/drp/4076478","DOIUrl":"https://doi.org/10.1155/drp/4076478","url":null,"abstract":"<p><strong>Background: </strong>Skin diseases are associated with reduced health-related quality of life (HRQoL) of children and their families. The Children's Dermatology Life Quality Index (CDLQI) questionnaire is a skin disease-specific measure of HRQoL in children. Our study aimed to translate the CDLQI into Amharic, culturally adapt, and evaluate the validity and reliability of the translation.</p><p><strong>Methods: </strong>This study was embedded within a larger hospital-based cohort study of cutaneous leishmaniasis (CL). Forward-backward translation procedures were conducted, followed by assessment of content and face validity. The psychometric properties were evaluated through reliability (internal consistency and interrater reliability), construct validity (including known-group, convergent, and discriminant validity), and responsiveness to change. Cronbach's alpha, intraclass correlation coefficient (ICC), Mann-Whitney <i>U</i> test, Kruskal-Wallis test, confirmatory factor analysis (CFA), and Wilcoxon paired rank test were used to assess internal consistency, interrater reliability, known-group validity, construct validity, and responsiveness to change validity, respectively.</p><p><strong>Results: </strong>The CDLQI showed acceptable content validity with a modified kappa between 0.7 and 0.9. In a pilot testing, children reported that the items in the translated Amharic version of the CDLQI were unambiguous. Among 188 enrolled participants, 129 (68.62%) were diagnosed with CL and 59 (31.38%) with other skin conditions. The median CDLQI score was 7 (IQR = 10). The overall Cronbach's alpha and ICC were 0.82 and 0.92, respectively. The median CDLQI score showed statistically significant differences between \"mild\" vs. \"severe\" and \"moderate\" vs. \"severe\" CL cases (<i>p</i> < 0.001), as well as between the number of lesions (single vs. multiple) (<i>p</i> = 0.034) and lesion size (< 40 mm vs. ≥ 40 mm) (<i>p</i> < 0.001). CFA showed acceptable convergent validity with most items loading strongly (0.50-0.74), and Heterotrait-Monotrait ratio values ranging from 0.614 to 0.744. The CDLQI median score significantly decreased from Day 1 (median = 9) to Day 90 (median = 4; <i>p</i> < 0.001).</p><p><strong>Conclusions: </strong>Our Amharic version of the CDLQI showed acceptable validity and reliability, supporting its use in clinical practice and research to assess the HRQoL of Amharic-speaking children with skin conditions in Ethiopia.</p>","PeriodicalId":11338,"journal":{"name":"Dermatology Research and Practice","volume":"2026 ","pages":"4076478"},"PeriodicalIF":2.0,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13624295/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149105674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Subcutaneous Rocatinlimab in Adults With Moderate-to-Severe Atopic Dermatitis: A Systematic Review and Meta-Analysis of Randomised Placebo-Controlled Trials.","authors":"Hong Jing Wang, Leong Seng Wang, Jordan Wei Lun Tan, Ee Syuen Wang, Yan Ye Lee","doi":"10.1155/drp/2160445","DOIUrl":"10.1155/drp/2160445","url":null,"abstract":"<p><strong>Background: </strong>Atopic dermatitis (AD) is a relapsing, chronic inflammatory skin disease. Rocatinlimab, an investigational anti-OX40 monoclonal antibody, has been evaluated for moderate-to-severe AD. This systematic review and meta-analysis aimed to evaluate the short-term efficacy and trial-reported safety of subcutaneous rocatinlimab in patients with moderate-to-severe AD.</p><p><strong>Methods: </strong>We searched PubMed, Ovid MEDLINE, Embase, Cochrane Central Register of Controlled Trials (CENTRAL) and ClinicalTrials.gov to identify randomised controlled trials (RCTs) comparing rocatinlimab with placebo in patients with moderate-to-severe AD. Only summary-level data from published reports were analysed. Outcomes of interest included treatment efficacy and safety. A random-effects model with Hartung-Knapp-Sidik-Jonkman adjustment was used for the primary pooled analyses. Exploratory subgroup analyses were conducted according to both dose and dosing frequency, with Wald-type confidence intervals used for subgroup-specific pooled estimates involving only two studies.</p><p><strong>Results: </strong>A total of 1767 patients from 3 RCTs were included. A total of 1305 patients (73.85%) received subcutaneous rocatinlimab. Rocatinlimab was associated with a significantly greater achievement of the pooled estimate for EASI-75 at Week 16 (OR 3.58, 95% CI 1.53-8.40; <i>p</i> = 0.02). The pooled estimate for the vIGA-AD score of 0 or 1 at Week 16 was directionally favourable but imprecise and did not reach statistical significance (OR 4.06, 95% CI 0.56-29.47; <i>p</i> = 0.09) No statistically significant differences were observed in serious adverse events (OR 1.60, 95% CI 0.41-6.26; <i>p</i> = 0.28) or treatment discontinuation due to adverse events (OR 1.28, 95% CI 0.14-11.60; <i>p</i> = 0.68), although confidence intervals were wide.</p><p><strong>Conclusion: </strong>In adults with moderate-to-severe AD, subcutaneous rocatinlimab demonstrated potential short-term treatment efficacy compared with placebo. However, the available evidence does not establish durable remission, prevention of recurrence, long-term disease modification or a favourable long-term benefit-risk profile. Given the subsequent discontinuation of the rocatinlimab clinical development programme following safety review, these findings should be interpreted cautiously as a synthesis of short-term trial evidence rather than support for future clinical use.</p>","PeriodicalId":11338,"journal":{"name":"Dermatology Research and Practice","volume":"2026 ","pages":"2160445"},"PeriodicalIF":2.0,"publicationDate":"2026-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13591123/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149016010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associated Factors and Dose-Response of Steroid-Induced Diabetes Mellitus in Dermatology Inpatients: A Retrospective Study.","authors":"Jingxi Zhang, Huimin Tang, Shantao Qiu, Yao Sun, Guan Jiang","doi":"10.1155/drp/4271696","DOIUrl":"10.1155/drp/4271696","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the prevalence and associated factors of steroid-induced diabetes mellitus (SDM) in dermatology inpatients receiving systemic glucocorticoid (GC) therapy, with particular focus on characterizing the dose-response relationship.</p><p><strong>Study design: </strong>Retrospective observational cohort study.</p><p><strong>Place and duration of study: </strong>Department of Dermatology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China, from August 2019 to October 2024.</p><p><strong>Methodology: </strong>A total of 293 patients treated with GCs were included, with 42 classified as having SDM and 251 as controls based on blood glucose monitoring. Data such as demographics, GC dosage, laboratory indices, and follow-up outcomes were analyzed by SPSS 26.0, R 4.4.1, and logistic regression analysis was applied to explore factors associated with the development of SDM. We modeled the nonlinear dose-response between average daily GC dose (methylprednisolone-equivalent) and SDM using multivariable logistic regression with restricted cubic splines, setting 0.6 mg/kg/day as the reference. All tests were two-sided, <i>p</i> < 0.05 indicates that the difference is statistically significant.</p><p><strong>Results: </strong>Among 293 patients, 42 (14.3%) developed SDM and 17 (5.8%) had impaired glucose regulation. SDM cases were older and had higher BMI, hypertension, family history of diabetes, higher average daily GC dose, and more frequent immunosuppressant use. Multivariate regression identified family history of diabetes (OR: 11.16), immunosuppressant use (OR: 3.48), average daily GC dose (OR: 29.13), and serum uric acid (OR: 1.007) as independent factors associated with SDM. The dose-response between average daily GC dose and SDM was significant (Wald <i>χ</i> ² = 18.48, df = 3, <i>p</i> = 0.0004); risk rose steeply beyond 1.0 mg/kg/day (e.g., 1.2 mg/kg/day: OR: 3.94, 95% CI: 1.44-10.66).</p><p><strong>Conclusion: </strong>SDM is prevalent among dermatology inpatients receiving GCs. High-risk patients may benefit from closer glucose monitoring and individualized dose adjustment; prospective studies are warranted to confirm these associations.</p>","PeriodicalId":11338,"journal":{"name":"Dermatology Research and Practice","volume":"2026 ","pages":"4271696"},"PeriodicalIF":2.0,"publicationDate":"2026-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13487544/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148789398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disclosing the Overall and Sex-Related Disease Burden and Treatment Needs of Patients With Anogenital Psoriasis: Results From the Case-Control PsoGen Study.","authors":"Neuza da Silva Burger, Matthias Augustin, Dagmar Wilsmann-Theis, Athanasios Tsianakas, Petra Staubach-Renz, Rachel Sommer","doi":"10.1155/drp/7159192","DOIUrl":"10.1155/drp/7159192","url":null,"abstract":"<p><strong>Purpose: </strong>Psoriasis lesions in the anogenital area affect about 33%-63% of the patients at some point in the disease course. Diminished quality of life (QoL), high depression rates, and sexual impairments have been described among patients with anogenital psoriasis, but specific treatment needs of these patients are often neglected in routine healthcare. This study aimed to compare patients with vs. without current anogenital lesions in terms of their sociodemographic and clinical characteristics, patient-reported outcomes (PROs) of disease burden, and patient-defined treatment needs/benefits and to identify clinical variables associated with PROs of disease burden.</p><p><strong>Patients and methods: </strong>The study had a cross-sectional case-control design. Patients aged ≥ 18 years with psoriasis were consecutively recruited in four German dermatology centers and were assigned to case or control group based on both patients' and physicians' reports of current anogenital involvement. PROs included the assessment of QoL impairments, treatment needs/benefits, depression/anxiety, perceived stigmatization, sexual frequency, and relationship/sexual impairments. Physicians assessed the severity of psoriasis and anogenital lesions (PASI and sPGA-G).</p><p><strong>Results: </strong>Participants were 294 patients with psoriasis, of which 159 (54.1%) had current anogenital lesions. Patients with anogenital lesions had higher disease severity, more comorbidities, but were less often treated with biologics. They also reported more QoL impairments, less treatment benefits, poorer mental health, and more sexual impairments. Specific treatment needs of patients with anogenital psoriasis were related to reducing physical and relationship/sexual impairments. Poorer PROs were explained at 25%-68% by higher disease severity, anogenital lesions, no biologic treatment, higher intensity of itching/burning, and lower frequency and more limitations in sexual activity.</p><p><strong>Conclusion: </strong>Within a patient-centered approach to dermatology care for psoriasis, clinical decisions, particularly patients' qualification for treatment with biologic drugs, should consider not only the location, extent, and severity of psoriasis lesions but also patient-reported symptoms, overall disease burden, and sexual limitations.</p>","PeriodicalId":11338,"journal":{"name":"Dermatology Research and Practice","volume":"2026 ","pages":"7159192"},"PeriodicalIF":2.0,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13470227/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148758497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Transcutol P on Percutaneous Absorption of Gel Containing Pure Synthetic Caffeine or Plant-Extracted Natural Caffeine.","authors":"Nastaran Seyyed Abbasi, Fatemeh Soltanmohammadi, Mohammad Charkhpour, Javad Shokri","doi":"10.1155/drp/3538935","DOIUrl":"10.1155/drp/3538935","url":null,"abstract":"<p><strong>Background: </strong>Caffeine, a safe methylxanthine, has been widely used for the treatment of skin diseases such as cellulite, hair loss, aging, and psoriasis. However, its skin penetration is low. Transcutol is a biocompatible, nonvolatile permeation enhancer which solubilize large number of drugs and does not change the integrity of the skin structure.</p><p><strong>Materials and methods: </strong>In this study, the skin permeability of synthetic and natural caffeine gels was compared by ex vivo experiments. Furthermore, Transcutol P was used as a permeation enhancer, and its impact on skin permeation enhancement was determined.</p><p><strong>Results: </strong>The skin penetration of caffeine from the formulation containing coffee extract, a type of natural caffeine, is higher than that of the formulation containing pure synthetic caffeine. This effect is likely due to the presence of coffee, which can act as a skin permeation enhancer. Additionally, the use of Transcutol P in a formulation containing coffee extract at a concentration of 2.5% caused the highest amount of flux. Therefore, the formulation of gel containing natural caffeine along with 2.5% Transcutol is optimal and can be used for further studies.</p><p><strong>Conclusion: </strong>It can be concluded that the addition of 2.5% Transcutol P in the formulation containing coffee extract resulted in the highest skin permeation.</p>","PeriodicalId":11338,"journal":{"name":"Dermatology Research and Practice","volume":"2026 ","pages":"3538935"},"PeriodicalIF":2.0,"publicationDate":"2026-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13451620/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148697289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"JAK Inhibitors for Treatment of Pyoderma Gangrenosum and Sweet Syndrome: A Systematic Review of Published Case Reports.","authors":"Seyed Mohammad Vahabi, Sama Heidari, Yalda Farahmand, Elnaz Pourgholi, Nika Kianfar, Huria Memari, Farzad Esmaeili, Saeed Bahramian, Ifa Etesami, Mahshid Sadat Ansari","doi":"10.1155/drp/7086209","DOIUrl":"10.1155/drp/7086209","url":null,"abstract":"<p><p>Neutrophilic dermatoses, including pyoderma gangrenosum (PG) and Sweet syndrome (SS), are inflammatory disorders characterized by neutrophilic infiltration without infection. Conventional therapies are often inadequate. We aim to evaluate the efficacy and safety of JAK inhibitors (JAK-I) in the treatment of PG and SS. The study was registered (PROSPERO-CRD420251113331), and a relevant search was conducted on PubMed/MEDLINE, Scopus, Web of Science, and Embase until July 27, 2025. Included studies were English language reports describing PG or SS treated with any JAK-I or cases of JAK-I-associated SS. Reviews, animal studies, and reports with insufficient clinical data were excluded. Four reviewers independently screened records. Data extraction included demographics, comorbidities, treatment regimens, outcomes, and adverse events. Risk of bias was assessed using the National Heart, Lung, and Blood Institute and Murad et al. tools through discussion-based consensus. Due to heterogeneous outcome definitions and small sample sizes, only descriptive synthesis was performed. Fifty-four reports, including 70 patients (59 PG, 5 SS) treated with JAK-I and 6 JAK-I-associated SS, were included. Across 43 PG studies, five JAK-Is-tofacitinib, upadacitinib, baricitinib, abrocitinib, and ruxolitinib-produced 33 complete and 26 partial responses. Twenty-six patients (44.1%) received monotherapy. Most patients (51/59; 86.4%) had at least one comorbidity. Adverse events occurred in 6 (10.1%), including anemia, hypertension, renal dysfunction, fatigue, and acneiform eruption. Among 11 SS reports, all 5 treated patients achieved complete resolution with baricitinib, ruxolitinib, or filgotinib. Six additional cases described ruxolitinib-associated SS, generally improving with corticosteroids or drug withdrawal. Most studies were rated good quality. Evidence is limited to small cases with heterogeneous outcome definitions, variable dosing, and inconsistent follow-up. JAK-Is are associated with clinical improvement in PG and selected SS cases and may serve as useful adjunct therapies, though caution is needed in patients with hematologic malignancies. Larger controlled studies are needed.</p>","PeriodicalId":11338,"journal":{"name":"Dermatology Research and Practice","volume":"2026 ","pages":"7086209"},"PeriodicalIF":2.0,"publicationDate":"2026-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13379896/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148497421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Dose Adjustment and Switching of Interleukin-17/23 Inhibitors for Thai Psoriasis.","authors":"Chayada Chaiyabutr, Teerapat Paringkarn, Thanakorn Woramongkol, Thrit Hutachoke, Narumol Silpa-Archa, Leena Chularojanamontri, Chanisada Wongpraparut","doi":"10.1155/drp/7998583","DOIUrl":"10.1155/drp/7998583","url":null,"abstract":"<p><p>Interleukin (IL)-17 and IL-23 inhibitors have transformed psoriasis care, delivering high clearance rates and quality-of-life gains. Nevertheless, inadequate response or adverse events can lead to treatment discontinuation or biologic switching. Dose modifications are also commonly implemented in routine practice to optimize efficacy, safety, and cost. The objective of this study is to characterize real-world outcomes of dose adjustment and switching of IL-17 and IL-23 inhibitors in Thai patients with psoriasis. We retrospectively reviewed 173 treatment courses with IL-17 inhibitors (secukinumab, ixekizumab, and brodalumab) and the IL-23 inhibitor guselkumab, documenting loading regimens, maintenance dosing, efficacy to Week 52, and switching events. At Week 12, full loading and standard maintenance dosing were associated with higher response rates in most cases. Ixekizumab was least often given with a full loading dose or standard maintenance dosing. By Weeks 24 and 52, reduced-dose regimens achieved comparable or better outcomes, suggesting careful patient selection. Thirty courses underwent biologic switching, predominantly for secondary failure. Intraclass switching among IL-17 inhibitors predominated. Switching from IL-23 to IL-17 inhibitors potentially outperformed both intraclass IL-17 switching or IL-17-to-IL-23 transitions. Erythrodermic psoriasis and higher baseline disease severity predicted switching, whereas incomplete loading doses and dose reductions did not. In conclusion, full loading and standard maintenance regimens facilitate early treatment response, while dose reduction in carefully selected patients can sustain long-term disease control without increasing the risk of switching.</p>","PeriodicalId":11338,"journal":{"name":"Dermatology Research and Practice","volume":"2026 ","pages":"7998583"},"PeriodicalIF":2.0,"publicationDate":"2026-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13379887/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148497498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Evidence of Upadacitinib Effectiveness in Moderate to Severe Atopic Dermatitis Patients in Saudi Arabia: A Retrospective Chart Review.","authors":"Shawky E L Saaty, Hamza Salim Alshehri, Osama Alsharif, Azhar Alali, Mohamad Ibrahim Fatani, Abdulmajeed Alajlan, Shereen Hammad, Ibrahim Elnahal, Tharwat Hamad, Ali Anwar, Kamal Ahmed","doi":"10.1155/drp/1238540","DOIUrl":"10.1155/drp/1238540","url":null,"abstract":"<p><strong>Background: </strong>Upadacitinib is an oral, selective, and reversible Janus kinase inhibitor that has demonstrated sustained efficacy and safety over 140 weeks in clinical trials for treating atopic dermatitis (AD). We evaluated the real-world effectiveness and impact on quality of life (QoL) of upadacitinib-based treatment therapy in patients with moderate-to-severe AD in Saudi Arabia (SA).</p><p><strong>Methods: </strong>A retrospective chart review was conducted at six sites. Data were collected from medical records of patients with AD aged ≥ 12 years who were treated with upadacitinib for a period of six months.</p><p><strong>Results: </strong>This study included 109 AD patients, with 15.6% (17/109) being adolescents (aged 12-17) and 84.4% (92/109) being adults (aged 18 and older). The mean age was 30.9 years (57.8% males). Based on disease severity assessment by the Eczema Area and Severity Index (EASI) scoring system, severe AD was observed in 65.1% of the patients. At six months, 83.5% of the patients had an EASI score ≤ 7 and EASI-75, EASI-90, and EASI-100 were achieved by 83.5%, 57.8%, and 12.8%, respectively. Dermatology life quality index (DLQI) 0/1 and pruritus Numerical Rating Scale (NRS) 0/1 at 6 months were achieved by 28.4% and 64.2%, respectively. Improvements were observed in the EASI, DLQI, and pruritus-NRS scores from baseline to the last visit (<i>p</i> < 0.001). The frequency of outpatient visits and filled prescriptions among AD patients remained stable after upadacitinib initiation, with a median (range) of 2 (1-20) outpatient visits before and 2 (1-9) after 6 months and a median (range) of 2 (1-12) filled prescriptions before compared with 2 (0-14) after 6 months. Adverse events (AEs) were reported in 10 patients, with acne being the most commonly observed.</p><p><strong>Conclusion: </strong>Upadacitinib-based treatment strategies showed an improvement in DLQI, EASI, and pruritus-NRS scores in patients with moderate-to-severe AD in SA. No new safety signals were identified, reinforcing its favorable benefit-risk profile in AD management.</p>","PeriodicalId":11338,"journal":{"name":"Dermatology Research and Practice","volume":"2026 ","pages":"1238540"},"PeriodicalIF":2.0,"publicationDate":"2026-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13373528/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148469617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}